[ad_1] I have great fun & satisfaction mentoring @IU_Health residents interested in #retina & #research. Congrats to these fantastic current & prior IU residents for this recent publication on a most-feared complication of #eye surgery:https://t.co/5juDSOKEov [ad_2] Source by Thomas Ciulla, MD, MBA Return to main …

[ad_1] RT @ThomasCiullaMD: Our study has generated much interest in #Luxturna #genetherapy #healtheconomics: Cost-effectiveness of Voretigene Nepa… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @ThomasCiullaMD: Honored to be interviewed by Dr. Wykoff of Retina Synthesis, on the journey through disruptive retina innovation in aca… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] RT @pharminews: Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potent… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Just published: Suprachoroidal DNA nanoparticle genetherapy preclinical study: https://t.co/XSE6Pydjjm Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium/Choroid in Rabbits | TVST | ARVO Journals #retina #suprachoroidal #GeneTherapy https://t.co/ERRLCc7Jd2 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] Honored to be interviewed by Dr. Wykoff of Retina Synthesis, on the journey through disruptive retina innovation in academia, clinical practice and industry… #retina #biotech #genetherapy https://t.co/LYP417LVx0 via @YouTube [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.

[ad_1] For COVID-19, mRNA vaccines have sprinted to approval. Historically, #retina played an important role in #RNA #therapy development, with the first approved ASO in 1998. We just published on potential RNA therapies for #AMD, #diabeticretinopathy & IRDs… https://t.co/S9TpaLYBsg [ad_2] Source by Thomas Ciulla, MD, …